SEC Form 4 · accession 0000899243-16-032645
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Lambing
Officer — See Remarks
Period of report
Oct 31, 2016
Accepted (ET)
Nov 2, 2016 · 5:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 31, 2016 | A | 1,263 | $10.03 | A | 123,583 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.51 | Nov 1, 2016 | A | 5,783 | A | Nov 1, 2016 | Jun 3, 2025 | Common Stock | 5,783 | 5,783 | D |
Explanation of responses
- F1Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.
- F2On June 4, 2015, the Reporting Person was granted an option to purchase 23,129 shares of Common Stock under the issuer's 2012 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On November 1, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 5,783 of the shares underlying such option.
Remarks
Senior Vice President, Non-Clinical and Pharmaceutical Development